Influence of paroxetine and cognitive/behavioral strategies in neurocardiogenic syncope and depression: a case report
Reg Arthur Williams, Juan F. Lopez
DOI: 10.4236/ojpsych.2011.13011   PDF    HTML     5,092 Downloads   9,487 Views  


OBJECTIVE: Neurocardiogenic syncope (NCS) is a condition where the patient has a temporary loss of consciousness or feelings of weakness and fatigue. There are triggers such as prolonged sitting or standing, pain, and heavy exercise, but often episodes are random. Treatments are limited and the use of specific serotonin reuptake inhibitors (SSRI) have had mixed results, but a limited number of studies have suggested that paroxetine may be effective in improving the symptoms of NCS. METHODS: This is a single case report of a 20-year old female who was diagnosed with NCS by a tilt test and treated conservatively with increased fluid and salt intake, and counter-pressure maneuvers. She was given one dose of sertraline, but immediately experienced disturbing visual images. She presented at the Depression Center with moderate depressive symptoms and was started on paroxetine and given cognitive/behavioral strategies to manage the NCS. RESULTS: Since the patient had a negative experience with a prior SSRI, she was started on a low dose of paroxetine and omega-3 fatty acids. She also was given a detailed explanation of NCS and a number of cognitive/behavioral strategies such as deep breathing, progressive relaxation, imagery, and sleep. CONCLUSION: After 2-weeks of the multi-faceted treatment approach, she had a significant decrease in her depressive symptoms. After 6-months, the patient had no episodes of syncope and no depressive symptoms. She was able to stand for long periods and exercise without feelings of weakness and fatigue. A multimodal approach may offer the best treatment strategy to achieve full remission in patients with NCS.

Share and Cite:

Williams, R. and Lopez, J. (2011) Influence of paroxetine and cognitive/behavioral strategies in neurocardiogenic syncope and depression: a case report. Open Journal of Psychiatry, 1, 75-78. doi: 10.4236/ojpsych.2011.13011.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Grubb, B.P. and McMann, M.C. (2001) The fainting phenomenon: Understanding why people faint and what can be done about it. Futura, New York.
[2] Neurocardiogenic syncope (2011).
[3] Savage, D.D., Corwin, L., McGee, D.L., Kannel, W.B. and Wolf, P.A. (1985) Epidemiologic features of isolated syncope: The Framingham Study. Stroke, 16, 626-629. doi:10.1161/01.STR.16.4.626
[4] Chen, L., Chen, M.H., Larson, M.G., Evans, J., Benjamin, E.J. and Levy, D. (2000) Risk factors for syncope in a community based sample (the framingham heart study). American Journal of Cardiology, 85, 1189-1193. doi:10.1016/S0002-9149(00)00726-8
[5] Deering, A (2007) Cheltenham syncope clinic.
[6] Alboni, P., Brignole, M., Menozzi, C., Raviele, A., DelRosso, A., Dinelli, M., Soluno, A. and Bottoni, N. (2001) Diagnostic value of history in patients with syncope with or without heart disease. Journal of American College of Cardiology, 37, 1921-1928. doi:10.1016/S0735-1097(01)01241-4
[7] Aydin, M.A., Maas, R., Mortensen, K., Steinig, T., Kleem, H., Risius, T., Meinertz, T., Willems, S., Morillo, C.A. and Ventura, R. (2008) Predicting recurrence of vasovagal syncope: A simple risk score for the clinical routine. Journal of Cardiovascular Electrophysiology, 20, 416-421. doi:10.1111/j.1540-8167.2008.01352.x
[8] Kuriachan, V., Sheldon, R.S. and Platonov, M. (2008) Evidence-based treatment for vasovagal syncope. Heart Rhythm, 5, 1609-1614. doi:10.1016/j.hrthm.2008.08.023
[9] Bolles, J.A., Gentlesk, P.J., Lewis, P.C., Ross, R.D. and Eckart, R.E. (2010) Resource utilization in the management of young patients with syncope in a combat theater of operations. Military Medicine, 175, 324-327.
[10] Linzer, M., Pontinon, M. and Gold, D.T. (1991) Impairment of physical and psychosocial health in recurrent syncope. Journal of Clinical Epidemiology, 44, 1037-1043. doi:10.1016/0895-4356(91)90005-T
[11] Di Girolamo, E., Di Iorio, C., Sabatini, P., Leonzio, L., Barbone, C. and Barsotti, A. (1999) Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: A randomized, double-bind, placebo-controlled study. Journal of the American College of Cardiology, 33, 1227-1230. doi:10.1016/S0735-1097(98)00694-9
[12] Di Girolamo, E., Di Iorio, C., Leonzio, L., Sabatini, P., Ranalli, G. and Barsotti, A. (1999) Effects of paroxetine in the treatment of refractory vasovagal syncope in young patients. Giornale Italiano Di Cardiologia, 29, 1472-1477.
[13] Foglia-Manzillo, G., Giada, Fr., Gaggioli, G., et al. (2004) Effacacy of tilt training in the treatment of neutrallymediated syncope. A randomized study. Europace, 6, 199-204. doi:10.1016/j.eupc.2004.01.002
[14] D’Antono, B.D., Dupuis, G., St-Jean, K., Levesque, K., Nadeau, R., Guerra, P., Thibault, B. and Kus, T. (2009) Prospective evaluation of psychological distress and psychiatric morbidity in recurrent vasovagal and unexplained syncope. Journal of Psychosomatic Research, 67, 213-222. doi:10.1016/j.jpsychores.2009.03.012
[15] Gracie, J., Newton, J. L., Norton, M., Baker, C. and Reeston, M. (2006) The role of psychological factors in response to treatment in neurocardiogenic (vasovagal) syncope. Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiace Cellular Electrophysiology of the European Society of Cardiology, 8, 636-643. doi:10.1093/europace/eul073
[16] Kiecolt-Glaser, J.K. (2010) Stress, food, and inflamemation: Psychoneuroimmunology and nutrition at the cutting edge. Psychosomatic Medicine, 72, 365-369. doi:10.1097/PSY.0b013e3181dbf489
[17] Takata, T.S., Wasmund, S.L., Smith, M.L., Li, J.M., Joglar, J.A., Banks, K., Kowal, R.C., Page, R.L. and Hamdan, M.H. (2002) Serotonin reuptake inhibitor (Paxil) does not prevent the vasovagal reaction associated with carotid sinus massage and/or lower body negative pressure in healthy volunteers. Circulation, 106, 1500-1504. doi:10.1161/01.CIR.0000029748.94931.96
[18] Linzer, M., Varia, I., Pontinen, M., et al. (1992) Medically unexplained syncope: Relationship to psychiatry illness. American Journal of Medicine, 92, S18-S25. doi:10.1016/0002-9343(92)90132-U
[19] Keller, M.B., McCullough, J.P., Klein, D.N., et al. (2002). A comparison of nefrzodone, the cognitive behavioral analysis system of psychotherapy, and their combination for the treatment of chronic depression. New England Journal of Medicine, 342, 1462-1470. doi:10.1056/NEJM200005183422001

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.